You searched for Gout - Page 7 of 90

Abstract Number: 0816 • ACR Convergence 2023
Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control Study
Ching-Tsai Lin¹, I-Chieh Chen², Wen-Nan Huang¹, Yi-Hsing Chen¹, Ching-Heng Lin² and Yi-Ming Chen¹, ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: This study aimed to investigate the interaction between the ABCG2 rs4148155 and SLC22A12 rs75786299 variants and their association with incident gout and nephrolithiasis in…
Abstract Number: 1012 • ACR Convergence 2023
Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Candace Feldman¹, Katherine Crum², Kaitlin Hanken³, Constance Fontanet⁴, Ellen Sears², Theresa Oduol², Seanna Vine², Juliana Mastrorilli², Gauri Bhatkhande², Julie Lauffenburger², Rebecca Oran⁵, Ted Robertson⁶, Wendy Wood⁷ and Niteesh Choudhry³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Center for Healthcare Delivery Sciences and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Darmouth Geisel School of Medicine, Hanover, NH, ⁵BCBS, Boston, MA, ⁶Ideas42, San Francisco, CA, ⁷USC, Los Angelos, CA
Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…
Abstract Number: 1037 • ACR Convergence 2023
Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy
Adwoa Dansoa Tabi-Amponsah¹, Sarah Stewart², Greg Gamble¹, Anthony Doyle³, Chang-Nam Son⁴, Kieran Latto¹, Lisa Stamp⁵, William Taylor⁶, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Auckland University of Technology, Auckland, New Zealand, ³Auckland District Health Board and University of Auckland, Auckland, New Zealand, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, UIJEONGBU, South Korea, ⁵University of Otago, Christchurch, New Zealand, ⁶University of Otago, Wellington, New Zealand
Background/Purpose: Preliminary gout remission criteria have been developed using OMERACT core outcome domains for long-term gout studies. This study aimed to identify variables that predict…
Abstract Number: 1102 • ACR Convergence 2023
Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
Amy S. Mudano¹, Jessica Ryan¹, Emily Holladay², Kathleen Methric³, Danielle Grauer⁴, Brian LaMoreaux³, Fenglong Xie¹ and Jeffrey R Curtis⁵, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Horizon Therapeutics, Deerfield, IL, ⁴Illumination Health, Boca Raton, FL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: Treatment of patients with gout can be complex and, given the episodic nature of gout attacks, gout patients may not always return for regular…
Abstract Number: 1105 • ACR Convergence 2023
Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients
Jinseok kim, Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea
Background/Purpose: Many studies have reported that gout and hyperuricemia are associated with an increase in all-cause mortality and cardiovascular mortality.Increased vascular stiffness is closely related…
Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Brian LaMoreaux¹, Chelsea McKibbon², Katie Obermeyer¹, Lissa Padnick-Silver¹, Gerald Smith², Jiaxuan Wang² and Haridarshan Patel¹, ¹Horizon Therapeutics, Deerfield, IL, ²Cytel Inc., Vancouver, BC, Canada
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…
Abstract Number: 1109 • ACR Convergence 2023
Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Blanka Stiburkova¹, Katerina Pavelcova², Jana Masinova¹, Marketa Pavlikova³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Praha 2, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Roy Fleischmann¹, James Cheng-Chung Wei², Zancong Shen³, sarah Morris⁴, Elizabeth Polvent⁵, Andrea Clouser-Roche⁴, Vijay Hingorani⁶, Rongzi Yan⁷, Shunqi Yan⁸, Robert Keenan⁹ and Li-Tain Yeh¹⁰, ¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ³Arthrosi Therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc, Irvine, CA, ⁸Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC, ¹⁰Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…
Abstract Number: 1113 • ACR Convergence 2023
Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients
Amanuel Kehasse¹, Sayali Dhamne², Michael LaValley³, Jean Liew² and Tuhina Neogi⁴, ¹Boston Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The management of gout remains poor despite the availability of effective medications and recommendation of a treat-to-target treatment strategy using of urate-lowering therapy (ULT).…
Abstract Number: 1114 • ACR Convergence 2023
Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout
Muhammad Danish Sarfraz, Lee Treanor, Savvas Nicolaou and Adnan Sheikh, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To find out if a Dual energy CT can detect monosodium urate deposition in carotid arteries and whether the presence of monosodium urate crystals…
Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Chio Yokose¹, Baijun Zhou¹, Natalie McCormick¹, Sruthi Tanikella¹, Minna Kohler², Janeth Yinh¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 1118 • ACR Convergence 2023
The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project
Silvia Sirotti¹, Charlotte Jauffret², Edoardo Cipolletta³, Daniele Cirillo⁴, Luca Ingrao⁴, Alessandro Lucia⁴, Antonella Adinolfi⁵, Debora Pireddu⁴, Emilio Filippucci⁶, Tristan Pascart², Sara Tedeschi⁷, Robert Terkeltaub⁸, Nicola Dalbeth⁹ and Georgios Filippou¹, ¹IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ²Saint-Philibert Hospital, Lille Catholic University, Lille, France, ³Polytechnic University of Marche, Ancona, Italy, ⁴Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy, ⁵Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁶Polytechnic University of Marche, Jesi, Italy, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of California San Diego, San Diego, CA, ⁹University of Auckland, Auckland, New Zealand
Background/Purpose: Despite prior attempts at standardising terminology of calcium pyrophosphate deposition (CPPD) disease (including the 2011 EULAR recommendations for CPPD terminology and diagnosis), many different…
Abstract Number: 1120 • ACR Convergence 2023
Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients
Natalie McCormick¹, Chio Yokose², Gregory Challener¹, Amit Joshi³, Sruthi Tanikella¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Channing Division of Network Medicine, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Despite rheumatology guidelines' emphasis on treat-to-target-serum-urate (SU) levels (<6 or <5 mg/dL, urate crystal sub-saturation points), this pathophysiology-based recommendation is not accepted in primary…
Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Roba Ghossan¹, Ouidade Aitisha Tabesh², Fouad Fayad², Pascal Richette³ and Thomas Bardin⁴, ¹COCHIN HOSPITAL, Paris, France, ²Hotel Dieu de France, Beirut, Lebanon, ³Lariboisière Hospital, Paris, France, ⁴Université de Paris Cité, Paris, France
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…

Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control Study

Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial

Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy

Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)

Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients

Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout

Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout

Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients

Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout

The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System

Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis

The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project

Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients

Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials

Simple Search Results